VistaGen Therapeutics (VTGN)
(Delayed Data from NSDQ)
$3.02 USD
+0.10 (3.42%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $3.03 +0.01 (0.33%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.02 USD
+0.10 (3.42%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $3.03 +0.01 (0.33%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Zacks News
Will VistaGen Therapeutics, Inc. (VTGN) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
VistaGen Therapeutics, Inc. (VTGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sage, Biogen Plan to File Zuranolone NDA for MDD in 2022
by Zacks Equity Research
Sage (SAGE) and partner Biogen are looking to get approval for zuranolone as an oral treatment for major depressive disorder. They will start rolling submission of an NDA in early 2022 for the candidate.
VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of 20.00% and -4.58%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Sage Stock Declines on Late-Stage Depression Study Data
by Zacks Equity Research
Sage is developing zuranolone as a potential treatment for major depression disorder in late-stage studies.
New Strong Sell Stocks for March 11th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of -40.00% and -4.85%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
VistaGen Up on Fast Track Designation for Anxiety Disorder Drug
by Zacks Equity Research
The FDA assigns a Fast Track status to VistaGen's (VTGN) neuroactive nasal spray PH94B for the on-demand treatment of social anxiety disorder. Stock surges.
Sage Therapeutics' Depression Drug Fails in Study, Stock Down
by Zacks Equity Research
Sage Therapeutics' (SAGE) phase III study on pipeline candidate SAGE-217 for the treatment of major depressive disorder fails to meet the primary endpoint.
Biotech Stock Roundup: MYOV & KRTX Surge, Pipeline Updates From VRTX, CELG & More
by Zacks Equity Research
Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.
VistaGen's (VTGN) Major Depressive Disorder Drug Disappoints
by Zacks Equity Research
VistaGen (VTGN) announces disappointing results from the ELEVATE study on MDD candidate, AV-101.
Biotech Stock Roundup: GILD, BIIB Present Data, VTGN Gains on Fast Track Status
by Zacks Equity Research
Data presentations by leading sector players take center stage this week.
VistaGen Up on Fast Track Designation to Pain Candidate
by Zacks Equity Research
VistaGen (VTGN) Fast Track designation for its pipeline candidate, AV-101, for treating neuropathic pain.
3 Drug/Biotech Stocks Up More Than 10% This Week
by Zacks Equity Research
The drugs/biotech sector is down this week due to broader market pressure, except a few stocks.
3 Drug/Biotech Stocks Up More Than 10% This Week
by Zacks Equity Research
The drugs/biotech sector is down this week due to broader market pressure, except a few stocks.